drugset / Trial / NCT06378060

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

NCT06378060

Phase 2 Recruiting 30 enrolled Hematology department of the 920th hospital
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.

Timeline

Start
2024-03-01
Primary completion
2026-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified 50 mg/kg
Background Fludarabine Small molecule 30 mg/m2
Background MMF Unknown 15 mg/kg
Background Melphalan Small molecule 100 mg/m2
Background Modified transplantation system Unknown
Background PTCY Unknown 25 mg/kg
Background Ruxolitinib Small molecule 2.5 mg

Indications